^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | SJ-C1044 (pan-RAF inhibitor, Angiogenesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity
Published date:
07/13/2023
Excerpt:
Our results showed that SJ-C1044 impaired the growth of all KRAS and BRAF mutant cancer cells, with IC50 values ranging from 160 to 628 nM...The results of these in vivo efficacy analyses suggested that SJ-C1044 inhibited the growth of tumors with KRAS or BRAF mutations.
DOI:
https://doi.org/10.3390/cimb45070371
